Companies · Biotechnology

Biotricity Inc.

REDWOOD CITY · Biotechnology

Diligence memoA one-page analyst read on Biotricity Inc. — recommendation, valuation, rhythm, risks.
$10.6M
Total raised · real
5
Rounds
0.8×
Latest step-up
Top 43%
Sector rank · raised
Series A
Latest stage · inferred · Mon Mar 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Biotricity Inc. looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.13× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Quiet
  • Last raise 2.3 yr ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Biotricity Inc. is one of 4291 Biotechnology companies tracked from REDWOOD CITY. By capital raised it ranks mid-pack (ahead of 58% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2024-03-25
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeed · 2016-03-31 Raised $1.1M (real) Modeled valuation $51M (est)$1.1M$51MSeed2016Pre-Seed · 2016-03-31 Raised $525K (real) Modeled valuation $29M (est)$525K$29MPre-Seed2016Seed · 2017-03-07 Raised $1.2M (real) Modeled valuation $55M (est)$1.2M$55MSeed2017Series A · 2019-12-19 Raised $6.0M (real) Modeled valuation $217M (est)$6.0M$217MSeries A2019Series A · 2020-07-14 Raised $1.3M (real) Modeled valuation $44M (est)$1.3M$44MSeries A2020Series A · 2024-03-25 Raised $1.0M (real) Modeled valuation $6.0M (est)$1.0M$6.0MSeries A2024+$525K+$1.2M+$6.0M+$1.3M+$1.0MCumulative $11M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.1M · 2016
Bridge · Seed-stage$525K · 2016smaller follow-on
Seed extension$1.2M · 2017
Series A$6.0M · 2019
Series A extension$1.3M · 2020
Series A extension$1.0M · 2024

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$6.0M
Base estimate est.
$1.1M
Conservative case
$13.7M
Upside case
$4.5M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $51.1M · 2016-03-312016Pre-Seed · modeled $29.0M · 2016-03-31Seed · modeled $54.7M · 2017-03-07Series A · modeled $216.9M · 2019-12-19Series A · modeled $44.5M · 2020-07-14Series A · modeled $6.0M · 2024-03-252024
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
2.3 yr
Elapsed time used
2.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
19 mo
Avg between rounds
$1.3M/yr
Capital velocity
10.3 yr
On record since
2016
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.5× above median
This company$10.6M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.2× of median
This company$1.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$6.0M
Sector median$64.2M

Raised more than 58% of sector peers (real $). Modeled value above 12% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #270 of 303.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)GeoVax Labs, Inc. · Series A Raised $39.1M · modeled $217.0M (est)Cellinfinity Bio Holding Company, LLC · Series A Raised $13.2M · modeled $215.9M (est)Adient Medical, Inc. · Series A Raised $18.2M · modeled $206.8M (est)Entegrion Inc · Series A Raised $22.7M · modeled $191.3M (est)BCD Bioscience, Inc. · Series A Raised $16.4M · modeled $188.9M (est)Pragma Biosciences Inc. · Series A Raised $14.5M · modeled $186.0M (est)MicroByre, Inc. · Series A Raised $16.1M · modeled $185.7M (est)Cardiac Insight, Inc. · Series A Raised $38.1M · modeled $183.8M (est)Cardiac Implants LLC · Series A Raised $13.5M · modeled $178.2M (est)Abintus Bio, Inc. · Series A Raised $13.7M · modeled $177.2M (est)Mosaic Biosciences, Inc. · Series A Raised $14.7M · modeled $176.1M (est)Mazen Animal Health Inc. · Series A Raised $13.5M · modeled $168.8M (est)Biotricity Inc. (this company) Raised $10.6M · modeled $6.0M (est)Biotricity Inc.
CompanyStageRaised · realValue · estvs peer med.
GeoVax Labs, Inc.Series A$39.1M$217.0M4.90×
Cellinfinity Bio Holding Company, LLCSeries A$13.2M$215.9M4.87×
Adient Medical, Inc.Series A$18.2M$206.8M4.67×
Entegrion IncSeries A$22.7M$191.3M4.32×
BCD Bioscience, Inc.Series A$16.4M$188.9M4.27×
Pragma Biosciences Inc.Series A$14.5M$186.0M4.20×
MicroByre, Inc.Series A$16.1M$185.7M4.19×
Cardiac Insight, Inc.Series A$38.1M$183.8M4.15×
Cardiac Implants LLCSeries A$13.5M$178.2M4.02×
Abintus Bio, Inc.Series A$13.7M$177.2M4.00×
Mosaic Biosciences, Inc.Series A$14.7M$176.1M3.98×
Mazen Animal Health Inc.Series A$13.5M$168.8M3.81×
Biotricity Inc. this companySeries A$10.6M$6.0M0.13×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.1M2016-03-31$5.8M$51.1M85%
Pre-Seed$525K2016-03-31$2.9M$29.0M85%
Seed$1.2M2017-03-07$6.2M$54.7M90%
Series A$6.0M2019-12-19$27.3M$216.9M90%
Series A$1.3M2020-07-14$5.7M$44.5M90%
Series A$1.0M2024-03-25$4.5M$6.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.1M2016-03-31
    • First recorded raise — entered as Seed.
    • 4 investors on this round.
  2. Pre-Seed$525K2016-03-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.2× smaller than the prior — bridge or down round.
    • 4 investors on this round.
  3. Seed$1.2M2017-03-07
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 2.3× larger than the prior — scaling up.
  4. Series A$6.0M2019-12-19
    • Raised again after 33 mo — slower than the ~14 mo sector norm.
    • Round 4.9× larger than the prior — scaling up.
    • 1 investor on this round.
  5. Series A$1.3M2020-07-14
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 4.8× smaller than the prior — bridge or down round.
    • 24 investors on this round.
  6. Series A$1.0M2024-03-25
    • Raised again after 44 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
Intelligence
2025 ~Q4
Modeled next raise · ~19mo cadence
$1.0M
Modeled next size est.range $1.0M$1.6M
0.8×
Last step-up
$1.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Steve Salmon5 other2020-07
David A. Rosa4 other2016-03
David Rosa4 other2020-07
Norman Betts2 other2020-07
Patricia Kennedy2 other2020-07
Ronald A. McClurg1 other2024-03
Chester A. White2024-03
John Ayanoglou2019-12
Norman M. Betts, M.D.2016-03
Waqaas Al-Siddiq2016-03
Registry & provenance

Biotricity Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1630113
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
NEUROONE MEDICAL TECHNOLOGIES CorpBiotechnologySeries A$21.2M$1.4Mnetwork2 shared operators · same sector · same stage
CHF Solutions, Inc.BiotechnologySeries A$33.0M$17.0Mnetwork2 shared operators · same sector · same stage
BioRestorative Therapies, Inc.BiotechnologySeries A$19.8M$4.0Mnetwork1 shared operator · same sector · same stage
TellBio, Inc.BiotechnologySeries A$11.0M$4.8Msame sector · same stage
Orion Biotechnology Canada Ltd.BiotechnologySeries A$11.2M$3.9Msame sector · same stage
Cba Pharma IncBiotechnologySeries A$10.0M$3.6Msame sector · same stage
Modifi Biosciences, Inc.BiotechnologySeries A$11.5M$4.9Msame sector · same stage
Hamilton Thorne Ltd.BiotechnologySeries A$11.5M$5.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Sensei Biotherapeutics, Inc.BiotechnologySeries D+$2.2B89%
Biostage, Inc.BiotechnologySeries A$1.8M89%
Geneticure Inc.BiotechnologyPre-Seed$11.0M88%
Resilient Biotics, Inc.BiotechnologySeries A$50.1M88%
BiomEdit, Inc.BiotechnologySeries B$82.0M88%
BioRegenx Inc.BiotechnologyPre-Seed$2.1M88%
BioAge Labs, Inc.BiotechnologySeries D+$2.4B88%
Biorez, Inc.BiotechnologySeries A$89.0M88%
Frequently asked
How much funding has Biotricity Inc. raised?
Biotricity Inc. has raised approximately $10.6M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Biotricity Inc.'s estimated valuation?
Provath's modeled valuation for Biotricity Inc. is approximately $6.0M (modeled range $1.1M–$13.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Biotricity Inc. at?
Biotricity Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Mar 25.
What does Biotricity Inc. do and where is it based?
Biotricity Inc. operates in the Biotechnology sector, based in REDWOOD CITY.
Explore related

See where Biotricity Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Biotricity Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.